Antiangiogenic therapies in endometriosis

S. Ferrero, N. Ragni, V. Remorgida

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Oral contraceptives, androgenic agents, progestins and gonadotropin- releasing hormone analogues have all been successfully used in the treatment of endometriosis. However, none of these drugs can eradicate the disease. It is widely accepted that the growth of newly formed blood vessels is essential for the establishment and growth of endometriotic lesions; therefore, inhibition of angiogenesis may offer a new option for treatment of this disorder. In this paper, we reviewed anti-vascular endothelial growth factor agents and other angiostatic drugs (i.e., TNP470, endostatin, anginex, rapamycin) that have been studied in laboratory and animal models of endometriosis. Although preliminary results are interesting, further investigations are required before clinical trials can be planned in humans.

Original languageEnglish
Pages (from-to)133-135
Number of pages3
JournalBritish Journal of Pharmacology
Volume149
Issue number2
DOIs
Publication statusPublished - Sep 14 2006

Fingerprint

Endometriosis
Endostatins
Angiogenesis Inhibitors
Progestins
Sirolimus
Growth
Oral Contraceptives
Contraceptive Agents
Gonadotropin-Releasing Hormone
Pharmaceutical Preparations
Vascular Endothelial Growth Factor A
Androgens
Blood Vessels
Animal Models
Clinical Trials
Therapeutics

Keywords

  • Angiogenesis
  • Endometriosis
  • Medical treatment
  • Rapamycin
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Antiangiogenic therapies in endometriosis. / Ferrero, S.; Ragni, N.; Remorgida, V.

In: British Journal of Pharmacology, Vol. 149, No. 2, 14.09.2006, p. 133-135.

Research output: Contribution to journalArticle

Ferrero, S. ; Ragni, N. ; Remorgida, V. / Antiangiogenic therapies in endometriosis. In: British Journal of Pharmacology. 2006 ; Vol. 149, No. 2. pp. 133-135.
@article{cdbb603e2c634915a01d78bcc1a25d63,
title = "Antiangiogenic therapies in endometriosis",
abstract = "Oral contraceptives, androgenic agents, progestins and gonadotropin- releasing hormone analogues have all been successfully used in the treatment of endometriosis. However, none of these drugs can eradicate the disease. It is widely accepted that the growth of newly formed blood vessels is essential for the establishment and growth of endometriotic lesions; therefore, inhibition of angiogenesis may offer a new option for treatment of this disorder. In this paper, we reviewed anti-vascular endothelial growth factor agents and other angiostatic drugs (i.e., TNP470, endostatin, anginex, rapamycin) that have been studied in laboratory and animal models of endometriosis. Although preliminary results are interesting, further investigations are required before clinical trials can be planned in humans.",
keywords = "Angiogenesis, Endometriosis, Medical treatment, Rapamycin, Vascular endothelial growth factor",
author = "S. Ferrero and N. Ragni and V. Remorgida",
year = "2006",
month = "9",
day = "14",
doi = "10.1038/sj.bjp.0706860",
language = "English",
volume = "149",
pages = "133--135",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Antiangiogenic therapies in endometriosis

AU - Ferrero, S.

AU - Ragni, N.

AU - Remorgida, V.

PY - 2006/9/14

Y1 - 2006/9/14

N2 - Oral contraceptives, androgenic agents, progestins and gonadotropin- releasing hormone analogues have all been successfully used in the treatment of endometriosis. However, none of these drugs can eradicate the disease. It is widely accepted that the growth of newly formed blood vessels is essential for the establishment and growth of endometriotic lesions; therefore, inhibition of angiogenesis may offer a new option for treatment of this disorder. In this paper, we reviewed anti-vascular endothelial growth factor agents and other angiostatic drugs (i.e., TNP470, endostatin, anginex, rapamycin) that have been studied in laboratory and animal models of endometriosis. Although preliminary results are interesting, further investigations are required before clinical trials can be planned in humans.

AB - Oral contraceptives, androgenic agents, progestins and gonadotropin- releasing hormone analogues have all been successfully used in the treatment of endometriosis. However, none of these drugs can eradicate the disease. It is widely accepted that the growth of newly formed blood vessels is essential for the establishment and growth of endometriotic lesions; therefore, inhibition of angiogenesis may offer a new option for treatment of this disorder. In this paper, we reviewed anti-vascular endothelial growth factor agents and other angiostatic drugs (i.e., TNP470, endostatin, anginex, rapamycin) that have been studied in laboratory and animal models of endometriosis. Although preliminary results are interesting, further investigations are required before clinical trials can be planned in humans.

KW - Angiogenesis

KW - Endometriosis

KW - Medical treatment

KW - Rapamycin

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33748493392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748493392&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0706860

DO - 10.1038/sj.bjp.0706860

M3 - Article

C2 - 16894342

AN - SCOPUS:33748493392

VL - 149

SP - 133

EP - 135

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 2

ER -